SL-T10 + GX-I7 + pembrolizumab

SL-T10 + GX-I7 + pembrolizumab is a combination investigational therapy consisting of two novel agents, **SL-T10** and **GX-I7**, with the approved checkpoint inhibitor **pembrolizumab**. - **Pembrolizumab** is a humanized monoclonal IgG4 kappa antibody that blocks the **programmed cell death protein 1 (PD-1)** receptor on T lymphocytes, releasing the brakes on the immune system and enhancing anti-tumor immune responses. It is FDA-approved and widely used for various cancers[1][3][5]. - **GX-I7** (also known as **efineptakin alfa**) is a long-acting interleukin-7 (IL-7) cytokine-based immune modulator under investigation for its ability to increase the number and activity of T cells, thus potentially improving the anti-tumor efficacy of immune checkpoint blockade. - **SL-T10** is a less-characterized investigational agent with sparse publicly available information. Its likely role in the combination is immunomodulation or tumor immune microenvironment alteration, but its exact mechanism and developer are not clearly established in available sources. This combination aims to synergize checkpoint inhibition (via PD-1 blockade), T cell expansion/potentiation (via IL-7 agonism), and possibly additional immunomodulatory effects (via SL-T10) for cancer immunotherapy.

Other names

SL-T10SL-T-10SL-T 10GX-I7GX-I-7GX-I 7pembrolizumabKeytruda